Kilitch Drugs to Divest Ethiopian Plant at $14 Million
India's Kilitch Drugs is selling its pharmaceutical manufacturing plant in Ethiopia for $14 million, according to a report by Birr Metrics published on 25 October 2026. No further details regarding the buyer, timeline or scope of the transaction were available from the source headline at the time of writing.
| Detail | Information |
|---|---|
| Seller | Kilitch Drugs (India) |
| Asset | Pharmaceutical manufacturing plant |
| Location | Ethiopia |
| Reported transaction value | $14 million |
| Reported by | Birr Metrics, 25 October 2026 |
Context: Indian Pharma's Presence in Africa
Indian pharmaceutical companies have historically established manufacturing operations across Africa to serve regional healthcare markets. A divestment of this scale reflects ongoing portfolio decisions by Indian producers as they evaluate the commercial returns from overseas facilities. No reasons for the sale were stated in the available headline, and no buyer has been named in the reported information.
Drugs and Pharmaceuticals Project Activity in India
Projects India tracks 1,795 projects in the Drugs and Pharmaceuticals sub-sector, with 14 added in the last 90 days. The pipeline spans the full project lifecycle, from early planning through to completion.
The stage breakdown of tracked projects illustrates where current capital deployment is concentrated:
- Under Approvals: 638 projects
- Construction Started: 362 projects
- Completed: 323 projects
- Approvals Received: 138 projects
- On Hold: 138 projects
- Planning: 98 projects
The largest share of activity — 638 projects — sits at the Under Approvals stage, indicating a substantial volume of capacity additions that have not yet entered construction. For suppliers and contractors, this represents an early-engagement window before procurement decisions are finalised.
Where the Activity Is: State-by-State Breakdown
Gujarat leads all Indian states in tracked pharmaceutical project count with 607 projects, well ahead of the next tier. Telangana and Andhra Pradesh follow with 244 and 231 projects respectively, reflecting the strength of established pharma clusters around Hyderabad. Karnataka accounts for 215 projects, Maharashtra for 167, and Himachal Pradesh for 59.
Recent projects entering the tracked pipeline include a Rs 195 crore API bulk drug and intermediates expansion by Chromo Laboratories India Private Limited in Sangareddy, Telangana, currently under approvals; a Rs 42 crore pharmaceutical facility by Centaur Pharmaceuticals Private Limited in South Goa where construction has started; and a Rs 31 crore bulk drugs manufacturing unit by Medilux Drugs Private Limited in Pithampur, Madhya Pradesh, also under approvals. Smaller greenfield investments in the Rs 7 crore to Rs 20 crore range are progressing across Ankleshwar, Tirunelveli, Chennai and Ahmedabad.
For a full view of active opportunities, see Projects India's Industrial Projects sector overview.
What this means for suppliers and contractors
The Kilitch Drugs divestment is an overseas transaction and does not directly create domestic procurement opportunity. However, it is a signal of how Indian pharmaceutical producers are managing their international asset portfolios, which can influence where capital is redeployed — including back into India-based capacity.
On the domestic side, the concentration of 638 pharmaceutical projects at the Under Approvals stage means a significant number of construction and equipment contracts are yet to be awarded. Gujarat, with 607 tracked projects, is the single most active geography for pharmaceutical capital expenditure and warrants priority attention from equipment suppliers, civil contractors and specialist engineering firms. Telangana and Andhra Pradesh together account for 475 tracked projects, making the greater Hyderabad corridor the second most important cluster.
Suppliers targeting API manufacturing — where several recent project additions are clustered — will find active opportunities in Gujarat's Ankleshwar zone, Maharashtra's Tarapur belt and Tamil Nadu. Projects at the Construction Started stage, currently numbering 362, represent near-term procurement for process equipment, utilities and civil works.
Readers tracking related investment activity in Indian pharmaceuticals may also find useful context in recent coverage of SJS Enterprises' Rs 81 crore pharma facility investment in Pune and Merck Life Science's €13 million Bengaluru manufacturing expansion.
Frequently asked questions
How much is Kilitch Drugs selling its Ethiopian plant for?
Kilitch Drugs is selling its pharmaceutical manufacturing plant in Ethiopia for $14 million, according to a report by Birr Metrics published on 25 October 2026. No buyer or timeline has been named in the available information.
Which Indian state has the most pharmaceutical projects?
Gujarat leads with 607 tracked pharmaceutical projects, followed by Telangana with 244 and Andhra Pradesh with 231, according to Projects India data. These three states together account for over half of all tracked projects in the sub-sector.
How many pharmaceutical projects are currently under approvals in India?
Projects India tracks 638 pharmaceutical projects at the Under Approvals stage, the largest share of any single stage in the sub-sector pipeline, representing significant near-term opportunity for suppliers once construction mandates are awarded.
